SPTX · Seaport Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| PureTech Health plc | ▼ Sell | Other | 16,685,013 Shares held | 5/4/2026 | View profile |
| ARCH Venture Partners XII, LLC 10% Owner | ▲ Buy | Open Market | 6,294,951 Shares held | 5/4/2026 | View profile |
| James Healy Director | ▼ Sell | Other | 2,731,538 Shares held | 5/4/2026 | View profile |
| PAUL STEVEN M Director | ▼ Sell | Other | 863,031 Shares held | 5/4/2026 | View profile |
| Gladstein Lana General Counsel | ▼ Sell | Other | 33,515 Shares held | 5/4/2026 | View profile |
| Loebel Antony Chief Medical Officer | ▼ Sell | Other | 20,109 Shares held | 5/4/2026 | View profile |
| Denice Torres Director | ▼ Sell | Other | 13,406 Shares held | 5/4/2026 | View profile |
| Robert J. Hombach Director | ▲ Buy | Open Market | 13,000 Shares held | 6/22/2026 | View profile |
| White Lauren Chief Financial Officer | ▼ Sell | Other | 6,702 Shares held | 5/4/2026 | View profile |
| Chen Michael Cunyuan Chief Scientific Officer | ▼ Sell | Other | 3,351 Shares held | 5/4/2026 | View profile |
Transaction History
| Robert J. Hombach | ▲ Buy | Open Market | 13,000 | $236K | 6/22/2026 |
| Denice Torres | ▼ Sell | Other | 13,406 | — | 5/4/2026 |
| ARCH Venture Partners XII, LLC | ▼ Sell | Other | 2,681,265 | — | 5/4/2026 |
| Chen Michael Cunyuan | ▼ Sell | Other | 3,351 | — | 5/4/2026 |
| Gladstein Lana | ▼ Sell | Other | 33,515 | — | 5/4/2026 |
| James Healy | ▼ Sell | Other | 804,379 | — | 5/4/2026 |
| James Healy | ▼ Sell | Other | 1,927,159 | — | 5/4/2026 |
| PureTech Health plc | ▼ Sell | Other | 965,255 | — | 5/4/2026 |
| PureTech Health plc | ▼ Sell | Other | 12,736,014 | — | 5/4/2026 |
| PAUL STEVEN M | ▼ Sell | Other | 67,031 | — | 5/4/2026 |
| White Lauren | ▼ Sell | Other | 6,702 | — | 5/4/2026 |
| PureTech Health plc | ▼ Sell | Other | 2,681,265 | — | 5/4/2026 |
| ARCH Venture Partners XII, LLC | ▼ Sell | Other | 2,513,686 | — | 5/4/2026 |
| ARCH Venture Partners XII, LLC | ▲ Buy | Open Market | 1,100,000 | $19.8M | 5/4/2026 |
| Loebel Antony | ▼ Sell | Other | 20,109 | — | 5/4/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Seaport Therapeutics Gains Analyst Attention Ahead of ECNP Data
Seaport Therapeutics has attracted new analyst coverage, with Canaccord Genuity and HC Wainwright both issuing price targets of $28 and $50 respectively. The company will present additional pharmacokinetic data from its Phase 1 GlyphAgo trial at the ECNP Congress in October. These developments add fresh information for investors to assess the drug’s progress. The stock remains near its 52‑week low, with a support level around $17.79.
Seaport Therapeutics Gains Analyst Attention Ahead of ECNP Data. Seaport Therapeutics has attracted new analyst coverage, with Canaccord Genuity and HC Wainwright both issuing price targets of $28 and $50 respectively. The company will present additional pharmacokinetic data from its Phase 1 GlyphAgo trial at the ECNP Congress in October. These developments add fresh information for investors to assess the drug’s progress. The stock remains near its 52‑week low, with a support level around $17.79.